Combined ligase IV A3V and T9I genotype distribution of controls and lymphoproliferative disorder cases, with odds ratios (OR) and 95% confidence intervals (95% CI)
| Ligase IV polymorphism | Controls (n=220) | ALL (n=70) | Lymphoma (n=364) | Multiple myeloma (n=270) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| A3V† | T9I† | No (%) | No (%) | OR* | 95% CI | No (%) | OR* | 95% CI | No (%) | OR* | 95% CI |
| *ORs estimated by logistic regression; †CC: wild type, CT: heterozygote, TT: homozygote variant; ‡SNA: sample non-amplifiable. | |||||||||||
| CC | CC | 148 (67.3) | 49 (70.0) | 1 | – | 244 (67.0) | 1 | – | 202 (74.8) | 1 | – |
| CC | CT | 34 (15.5) | 12 (17.1) | 1.07 | 0.51 to 2.22 | 67 (18.4) | 1.20 | 0.75 to 1.89 | 42 (15.6) | 0.91 | 0.55 to 1.49 |
| CC | TT | 7 (3.2) | 0 (0.0) | – | – | 4 (1.1) | 0.35 | 0.10 to 1.20 | 2 (0.7) | 0.21 | 0.04 to 1.02 |
| CT | CC | 1 (0.5) | 0 (0.0) | – | – | 3 (0.8) | 1.82 | 0.19 to 17.66 | 1 (0.4) | 0.73 | 0.05 to 11.81 |
| CT | CT | 24 (10.9) | 9 (12.9) | 1.13 | 0.49 to 2.60 | 41 (11.3) | 1.04 | 0.60 to 1.78 | 18 (6.7) | 0.55 | 0.29 to 1.05 |
| CT | TT | 6 (2.7) | 0 (0.0) | – | – | 3 (0.8) | 0.30 | 0.07 to 1.23 | 1 (0.4) | 0.12 | 0.01 to 1.03 |
| TT | CC | 0 (0.0) | 0 (0.0) | – | – | 0 (0.0) | – | – | 0 (0.0) | – | – |
| TT | CT | 0 (0.0) | 0 (0.0) | – | – | 0 (0.0) | – | – | 0 (0.0) | – | – |
| TT | TT | 0 (0.0) | 0 (0.0) | – | – | 0 (0.0) | – | – | 1 (0.4) | – | – |
| SNA‡ | – | – | 2 | 3 | |||||||